Men's Health

The benefits of robot-assisted partial nephrectomy outweigh the health care and surgical costs, a new study found.

Earlier, more aggressive radiation therapy is recommended in prostate cancer patients with detectable PSA following radical prostatectomy, say the authors of a recently published study.

The muddy waters of patient selection and timing of post-prostatectomy radiation therapy may be clearer. Find out how.

A newer androgen receptor blocker significantly increases survival versus a first-generation agent in men with metastatic castration-resistant prostate cancer, data show.

The analysis looked at intracytoplasmic sperm injection use and reproductive outcomes between 1996 and 2012. fertilization. Learn why

A literature review has found no evidence that testosterone therapy increases cardiovascular risk.

A patient with an abnormal PSA level transferred to another physician's care and was never told of his result. Two and a half years later, a biopsy revealed Gleason 9 prostate cancer.

Use of the urethral lift as a treatment for BPH provided rapid improvement in symptoms, flow, and quality of life that were sustained at 2 years in a multicenter study.

A large-scale study provides new evidence that targeted MRI ultrasound fusion prostate biopsy increases detection of high risk prostate cancers while decreasing detection of low-risk cancers. "More reliable diagnosis"

A newly published analysis “opens a huge opportunity for the discovery of new biomarkers” for multiple cancers, including aggressive prostate cancer, a leading urologic cancer expert says.

More than 90% of men whose lower urinary tract symptoms (LUTS) progress do not seek treatment for their symptoms, according to recent study results that one expert cautioned against overinterpreting.

Palmetto GBA, a national contractor that administers Medicare benefits, has issued a positive coverage policy through the MolDX Program for the Decipher prostate cancer classifier, developer GenomeDx Biosciences reported.

While it is often difficult to defend a case involving the removal of an organ for cancer that is then determined to be cancer free, the added claim of lack of informed consent for the procedure does not aid the defense in these lawsuits.

A novel imaging technique may prove more effective than current magnetic resonance imaging approaches for localizing prostate tumors, researchers say.

A combination vaccine and androgen ablation therapy is showing promise in some patients with prostate cancer.

An advanced prostate cancer treatment protocol incorporating testosterone shows promise for treating the disease and reversing resistance to androgen deprivation therapy.

In this video, Edward Karpman, MD, shows how he performs microsurgical two-layer vasovasostomy to reconstruct the vas deferens after vasectomy.

In this video, Daniel H. Williams, IV, MD, demonstrates the use of microsurgical epididymovasostomy (two-suture intussusception technique) when no sperm are found in the testicular end of the vas deferens at the time of microsurgical reconstruction.

Advances in the diagnosis and treatment of prostate cancer are among the great medical accomplishments of the latter part of the 20th century and beginning of the 21st. Five-year survival rates for newly diagnosed loco-regional cancer advanced from 68% in 1975-’77 to 83% in 1987-’89 to nearly 100% in 2003-’09, according to the American Cancer Society. This victory, however impressive, is incomplete.

The addition of radiation treatment to hormone therapy reduces mortality in older men with locally advanced prostate cancer compared with hormone therapy alone, according to a recently published study in the Journal of Clinical Oncology.

A genomic test for prostate cancer was able to predict rapid metastatic disease in node-negative, high-risk men managed by radical prostatectomy without adjuvant therapy in a recently published study.

New products and services from Samsung Electronics America, Syneron Medical, American Medical Systems, New Star, Buffalo Filter, Cook Medical, Endo International, Trimel BioPharma Metamark, and the National Comprehensive Cancer Network.

The rate of prostate biopsy declined steadily and significantly over a contemporary 10-year period, results of a retrospective longitudinal review of data from the Veterans Health Administration show.

Our January 2015 installment in the ongoing "New Frontiers in Prostate Cancer" series focuses on the challenges presented by high-risk disease. Here are some video resources on high-risk prostate cancer.

Our January 2015 installment in the ongoing "New Frontiers in Prostate Cancer" series focuses on the challenges presented by high-risk disease. Here are some recommended articles about the diagnosis and treatment of high-risk prostate cancer.

In this interview, Arie Belldegrun, MD, discusses the benefits of cancer immunotherapy, the importance of a multidisciplinary treatment approach, and what the future holds for this treatment.

The 2015 omnibus spending bill canceled a $10 million appropriation for the Independent Payment Advisory Board (IPAB). Congress also approved a bill that cuts Medicare funding for vacuum erection systems. Rationing care, whether undertaken by the IPAB or Congress, must be opposed when it arbitrarily selects services based on public perception and not medical necessity, writes Ross E. Weber of the AACU.

Drugs and devices in the pipeline from Actavis, Genomic Health, Lipella Pharmaceuticals, Polaris Group, Innocrin Pharmaceuticals, OncoGenex Pharmaceuticals, Heat Biologics, Repros Therapeutics, and Sophiris Bio.

Urology Times continues its "Year in Review" series with a look at the most-read men's health articles of 2014.

Results of a randomized, double-blind, placebo-controlled, phase IV study provide further confirmation that the erectogenic effect of the phosphodiesterase-type-5 inhibitor avanafil (Stendra) has a quick onset.